CJC-1295/Ipamorelin– SYNERGISTIC RESEARCH PEPTIDE COMBINATION FOR GROWTH HORMONE SIGNALING STUDIES

Scientific Overview of CJC-1295/Ipamorelin

CJC-1295 and Ipamorelin are complementary research peptides commonly evaluated together in in-vitro and in-vivo experimental studies exploring the regulation of the growth hormone (GH) axis.
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analog.

Ipamorelin is a selective ghrelin receptor agonist (GHSR agonist) studied for its ability to stimulate GH release through independent but converging pathways.

Research examining this peptide combination has focused on:

• Synergistic GH Axis Modulation – comparative analysis of pituitary signaling and pulsatile GH release (Teichman et al., 2006)
• Receptor Specificity and Selectivity – study of CJC-1295 binding to GHRH receptors and Ipamorelin activation of GHSR-1a pathways (Depoortere et al., 1997)
• Endocrine Signal Integration – investigation of combined effects on cAMP and intracellular calcium signaling cascades (Frohman et al., 2001)